-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: Now, the industry order is gradually established, slow disease management into the era of rational cultivationAuthor: Zhang Jingthe digital management of diabetes once hot, fierce competition for a period of time even known as the "sugar war." However, after the roaring noise, the runners were eventually eliminatedNowadays, the industry order is gradually established, slow disease management has entered the era of rational cultivationin the field of digital management of diabetes, Huano Zhisheng from the beginning of the establishment of a different, when the "100 sugar war" intensified, he stayed out of the matter, silently research and development; "We are a technology company focused on diabetes, and we have developed a digital diabetes management solution designed to help healthcare organizations manage people with diabetes more effectively and easily," said Liu Yudou, founder ofHuano Zhisheng"Why isWarno Zhisheng different?" What are the considerations in making decisions? What are the characteristics of the strategic layout? To learn more about Huanor's winning book, Arterial Network gave it an exclusive first in-depth interviewgrab C-side users is not yet mature, focus ingress on b-side back-to-service diabetics
in 2014, Botten Pharmaceuticals went public, in the company's executive work of Liu Weidou began to shift to investment, incubation of new medical business, and his main focus is on the digital medical fieldat this time, by virtue of the work, Liu Yudou learned about many domestic diabetes management enterprises, and went abroad to meet livongo and other mainstream slow disease digital enterprisecore team, to investigate and researchThrough exchanges with a number of entrepreneurs in the field of diabetes management, he believes that the domestic model of selling medical devices and medicines to the C end is difficult to runreasons for several reasons: First, most of these models by allowing patients to consult doctors in the APP to attract patients, however, doctors usually have a large number of outpatient, inpatient and academic work, online consultation and the doctor's job of diabetes management combined, into a doctor's "sideline", only in the case of high subsidies, there are some doctors willing to pay extra time to deal with patient consultationAnd the high user subsidy costs, the harvest is only a kind of online light consultation, it is difficult to form a truly valuable diabetes management services for patientssecond, although diabetics because of the doctor recommended to download a piece of software, not necessarily in the software to buy products, it is likely to be high credit, good service, cheap large e-commerce platform to buyThis has led many start-ups to design a profit model that can only be a castle in the skyagain, the diabetes products that e-commerce cannot cover are mainly prescription drugs, but at the time prescription drugs could not be circulated over the Internet finally, to do online shopping malls, we need to consider logistics system, supply chain and other issues, which has gone beyond the original intention of digital management innovation of diabetes Therefore, Liu Yudou believes that the "100 sugar war" period, the initiative to rob the C-side users is a wrong path after a long investigation , he found that the large number of diabetes management apps on the market were far from those defined by foreign-defined digital therapies and professional disease management applications Most diabetes management APP blood sugar records, diet records, exercise records and other functions are flooded by the mall and advertising, not to mention personalized advice and other features that reflect the advantages of digital therapy the technical threshold of diabetes management is not high, resulting in many people piled into the field, resulting in vicious competition The comprehensive threshold of diabetes management is very high, the need to reshape the treatment and management process of diabetes, understand the pain points in the details of diagnosis and treatment, explore the needs of customers .. Only by completing the trivial tasks, taking into account every detail of diabetes management, and identifying how to reshape today's diabetes management through technology, can we make truly valuable digital diabetes management innovations However, these details are not done for most people who pile up in the field, which also causes patients (users) to lose confidence in similar products and the cost of market education is even more expensive after a long period of consideration, Liu Decided not to invest in incubation-related projects for the time being, because the field is not yet mature But he also did not give up attention to diabetes management, but for a long time to look at the development of foreign enterprises, thinking about the gap between domestic and foreign environment the digital field of diabetes, which is developing rapidly abroad and is difficult at home And the domestic and United States in addition to the medical payment system, the medical system has a huge difference, patient conditions, treatment concepts and treatment strategies, related guidelines are basically the same Why is the pace of development in diabetes management so different from that of the United States at home and in the United States? " As the research on the digital management of diabetes becomes more and more deeper, I think the domestic enterprises that have been studied before have done too little "We have to see both different parts of China and the United States, but also see similar places, and build business logic in similar places "
2016, "Love to snooze" Liu Weibean left the well-paid Botten Pharmaceuticals, founded Huano Zhisheng, determined to make a career in the field of diabetes management tailor-made sugar control system for hospitals, greatly improve the efficiency of diabetes management
in 2016, a large number of enterprises in the field of diabetes management disappeared, but also a part of the birth of enterprises When everyone is considering whether to abandon the C-side market, Huano Zhisheng has begun to develop B-side-oriented products Liu Weizu introduced: "We have not been directly from the beginning of the start-up C-side idea, because this is not a good path." And for the hospital, the endocrinology department of diabetes management business digital upgrade, enabling medical institutions, to help hospitals more effective and convenient management of patients, in order to benefit the vast number of people with diabetes, but also can catch the hospital information ride "
However, digital management of diabetes is very difficult, the need to reshape the diagnosis and management of diabetes, management processes, in-depth understanding of patient needs, doctor needs, hospital needs, and digital therapy has achieved some success." To this end, Huano Zhisheng from the beginning to create a professional can lead the innovation of the core founding team, and set up three major centers in the organizational structure: product research and development center, technology center, project operations center Product Research and Development Center consists of domestic and foreign experts, consultants and experienced professionals, mainly responsible for researching the field of digitalization, how to manage diabetes through digital technology The results of its research are developed by the Technology Center as a prototype of the product Technology Center is composed of software, hardware, embedded integration and other cross-professional experts, mainly responsible for the idea of productization, to solve compatibility, intelligent algorithms and other challenges The Project Operations Center is to gain insight into the needs of various organizations and help medical institutions import and use products after a long period of research and development, In July 2019, Huano Zhisheng launched The Re-Control Sugar (formerly known as Rui Sugar) - a professional diabetes full-course management system for medical institutions The system can help hospitals create their own diabetes management model and treatment process Liu Yuzu told Arterial.com: "Huano Zhisheng will reshape the hospital's diabetes diagnosis and treatment process and management process, to help the hospital from the entrance of diabetes, examination, diagnosis, treatment programs, diabetes management and other aspects of digital upgrading." Forming a new continuous management model of blood sugar coverage in outpatient, remote and inpatient links At the same time, Huano Zhisheng's project operations center will help hospitals import products and guide hospitals in the use of the re-control sugar system "
Core Sugar System is compatible with a wide range of blood glucose meters, CGM, insulin pumps and health applications from which patient health data, dietary activities, etc can be obtained With this data, doctors can develop personalized treatment options for patients For doctors, the population management and risk assessment provided by the Re-Sugar System can significantly improve the efficiency and quality of diabetes management Managing the clinical data accumulated by diabetic patients can support the improvement of doctors' clinical skills and can also be used for clinical scientific research it is worth mentioning that the risk assessment function can make appropriate recommendations based on the patient's critical situation For example, the patient's condition is very critical, the risk assessment function will alert the patient himself and his relatives, and alarm the health care team within 4 hours of remote intervention and guidance; at the same time, Huano Zhisheng will be tailored according to the hospital's medical resources combined with outpatient, remote and inpatient scenarios under the full blood sugar management model, so that the hospital when using the system is handy business model fully verified, facing the future, Huano Zhisheng into accelerated development at present, Huana Zhisheng has more than 30 customers in the country, to achieve balance of payments At the same time, with the field of diabetes well-known pharmaceutical enterprises and medical device enterprises reached a strategic cooperation agreement, joint research and development and joint promotion, to provide customers with a better and complete overall solution in addition, the company entered the Chongqing market, in the city's cloud computing big data association with the help of the integration of relevant industry resources, and the city's relevant units actively declare municipal projects future, Huano Zhisheng will continue to focus on the field of diabetes management, innovation of the sugar control system, and accelerate the promotion, improve market penetration finally, Liu said: "Huano Zhisheng's current economic situation is healthy, products, technology and business models have been more fully verified, is about to enter a period of rapid expansion, this year (2020) to carry out B-round financing, to accelerate development, rapid occupation of the market." Previously, Huano Zhisheng received round A financing from the Pharmaceutical Listed Company Industry Fund in 2017 Responsible Editor: Jenny Turtle related labels: national , chronic disease management , digital medical 0
0